A randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours

British Journal of Cancer, Published online: 13 May 2023; doi:10.1038/s41416-023-02269-zA randomised phase 2 study of continuous or intermittent dosing schedule of imatinib re-challenge in patients with tyrosine kinase inhibitor-refractory gastrointestinal stromal tumours

https://www.nature.com/articles/s41416-023-02269-z

Source: British Journal of Cancer - May 13, 2023 Category: Cancer & Oncology Authors: Hyung-Don Kim Changhoon Yoo Min-Hee Ryu Yoon-Koo Kang Source Type: research